Cargando…

Safety and Effectiveness of Abatacept in a Prospective Cohort of Patients with Rheumatoid Arthritis–Associated Interstitial Lung Disease

Objective: To prospectively evaluate the safety and efficacy profile of abatacept in patients with rheumatoid arthritis–associated interstitial lung disease (RA-ILD). Methods: We performed a prospective observational multicenter study of a cohort of patients with RA-ILD treated with abatacept betwee...

Descripción completa

Detalles Bibliográficos
Autores principales: Mena-Vázquez, Natalia, Rojas-Gimenez, Marta, Fuego-Varela, Clara, García-Studer, Aimara, Perez-Gómez, Nair, Romero-Barco, Carmen María, Godoy-Navarrete, Francisco Javier, Manrique-Arija, Sara, Gandía-Martínez, Myriam, Calvo-Gutiérrez, Jerusalem, Morales-Garrido, Pilar, Mouriño-Rodriguez, Coral, Castro-Pérez, Patricia, Añón-Oñate, Isabel, Espildora, Francisco, Aguilar-Hurtado, María Carmen, Hidalgo Conde, Ana, Arnedo Díez de los Ríos, Rocío, Cabrera César, Eva, Redondo-Rodriguez, Rocío, Velloso-Feijoo, María Luisa, Fernández-Nebro, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9313094/
https://www.ncbi.nlm.nih.gov/pubmed/35884786
http://dx.doi.org/10.3390/biomedicines10071480
_version_ 1784753994850107392
author Mena-Vázquez, Natalia
Rojas-Gimenez, Marta
Fuego-Varela, Clara
García-Studer, Aimara
Perez-Gómez, Nair
Romero-Barco, Carmen María
Godoy-Navarrete, Francisco Javier
Manrique-Arija, Sara
Gandía-Martínez, Myriam
Calvo-Gutiérrez, Jerusalem
Morales-Garrido, Pilar
Mouriño-Rodriguez, Coral
Castro-Pérez, Patricia
Añón-Oñate, Isabel
Espildora, Francisco
Aguilar-Hurtado, María Carmen
Hidalgo Conde, Ana
Arnedo Díez de los Ríos, Rocío
Cabrera César, Eva
Redondo-Rodriguez, Rocío
Velloso-Feijoo, María Luisa
Fernández-Nebro, Antonio
author_facet Mena-Vázquez, Natalia
Rojas-Gimenez, Marta
Fuego-Varela, Clara
García-Studer, Aimara
Perez-Gómez, Nair
Romero-Barco, Carmen María
Godoy-Navarrete, Francisco Javier
Manrique-Arija, Sara
Gandía-Martínez, Myriam
Calvo-Gutiérrez, Jerusalem
Morales-Garrido, Pilar
Mouriño-Rodriguez, Coral
Castro-Pérez, Patricia
Añón-Oñate, Isabel
Espildora, Francisco
Aguilar-Hurtado, María Carmen
Hidalgo Conde, Ana
Arnedo Díez de los Ríos, Rocío
Cabrera César, Eva
Redondo-Rodriguez, Rocío
Velloso-Feijoo, María Luisa
Fernández-Nebro, Antonio
author_sort Mena-Vázquez, Natalia
collection PubMed
description Objective: To prospectively evaluate the safety and efficacy profile of abatacept in patients with rheumatoid arthritis–associated interstitial lung disease (RA-ILD). Methods: We performed a prospective observational multicenter study of a cohort of patients with RA-ILD treated with abatacept between 2015 and 2021. Patients were evaluated using high-resolution computed tomography and pulmonary function tests at initiation, 12 months, and the end of follow-up. The effectiveness of abatacept was evaluated based on whether ILD improved, stabilized, progressed, or was fatal. We also evaluated factors such as infection, hospitalization, and inflammatory activity using the 28-joint Disease Activity Score with the erythrocyte sedimentation rate (DAS28-ESR). Cox regression analysis was performed to identify factors associated with progression of lung disease. Results: The study population comprised 57 patients with RA-ILD treated with abatacept for a median (IQR) of 27.3 (12.2–42.8) months. Lung disease had progressed before starting abatacept in 45.6% of patients. At the end of follow-up, lung disease had improved or stabilized in 41 patients (71.9%) and worsened in 13 (22.8%); 3 patients (5.3%) died. No significant decreases were observed in forced vital capacity (FVC) or in the diffusing capacity of the lung for carbon monoxide (DLCO).The factors associated with progression of RA-ILD were baseline DAS28-ESR (OR [95% CI], 2.52 [1.03–3.12]; p = 0.041), FVC (OR [95% CI], 0.82 [0.70–0.96]; p = 0.019), and DLCO (OR [95% CI], 0.83 [0.72–0.96]; p = 0.018). Only 10.5% of patients experienced severe adverse effects. Conclusion: Pulmonary function and joint inflammation stabilized in 71% of patients with RA-ILD treated with abatacept. Abatacept had a favorable safety profile.
format Online
Article
Text
id pubmed-9313094
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-93130942022-07-26 Safety and Effectiveness of Abatacept in a Prospective Cohort of Patients with Rheumatoid Arthritis–Associated Interstitial Lung Disease Mena-Vázquez, Natalia Rojas-Gimenez, Marta Fuego-Varela, Clara García-Studer, Aimara Perez-Gómez, Nair Romero-Barco, Carmen María Godoy-Navarrete, Francisco Javier Manrique-Arija, Sara Gandía-Martínez, Myriam Calvo-Gutiérrez, Jerusalem Morales-Garrido, Pilar Mouriño-Rodriguez, Coral Castro-Pérez, Patricia Añón-Oñate, Isabel Espildora, Francisco Aguilar-Hurtado, María Carmen Hidalgo Conde, Ana Arnedo Díez de los Ríos, Rocío Cabrera César, Eva Redondo-Rodriguez, Rocío Velloso-Feijoo, María Luisa Fernández-Nebro, Antonio Biomedicines Article Objective: To prospectively evaluate the safety and efficacy profile of abatacept in patients with rheumatoid arthritis–associated interstitial lung disease (RA-ILD). Methods: We performed a prospective observational multicenter study of a cohort of patients with RA-ILD treated with abatacept between 2015 and 2021. Patients were evaluated using high-resolution computed tomography and pulmonary function tests at initiation, 12 months, and the end of follow-up. The effectiveness of abatacept was evaluated based on whether ILD improved, stabilized, progressed, or was fatal. We also evaluated factors such as infection, hospitalization, and inflammatory activity using the 28-joint Disease Activity Score with the erythrocyte sedimentation rate (DAS28-ESR). Cox regression analysis was performed to identify factors associated with progression of lung disease. Results: The study population comprised 57 patients with RA-ILD treated with abatacept for a median (IQR) of 27.3 (12.2–42.8) months. Lung disease had progressed before starting abatacept in 45.6% of patients. At the end of follow-up, lung disease had improved or stabilized in 41 patients (71.9%) and worsened in 13 (22.8%); 3 patients (5.3%) died. No significant decreases were observed in forced vital capacity (FVC) or in the diffusing capacity of the lung for carbon monoxide (DLCO).The factors associated with progression of RA-ILD were baseline DAS28-ESR (OR [95% CI], 2.52 [1.03–3.12]; p = 0.041), FVC (OR [95% CI], 0.82 [0.70–0.96]; p = 0.019), and DLCO (OR [95% CI], 0.83 [0.72–0.96]; p = 0.018). Only 10.5% of patients experienced severe adverse effects. Conclusion: Pulmonary function and joint inflammation stabilized in 71% of patients with RA-ILD treated with abatacept. Abatacept had a favorable safety profile. MDPI 2022-06-22 /pmc/articles/PMC9313094/ /pubmed/35884786 http://dx.doi.org/10.3390/biomedicines10071480 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Mena-Vázquez, Natalia
Rojas-Gimenez, Marta
Fuego-Varela, Clara
García-Studer, Aimara
Perez-Gómez, Nair
Romero-Barco, Carmen María
Godoy-Navarrete, Francisco Javier
Manrique-Arija, Sara
Gandía-Martínez, Myriam
Calvo-Gutiérrez, Jerusalem
Morales-Garrido, Pilar
Mouriño-Rodriguez, Coral
Castro-Pérez, Patricia
Añón-Oñate, Isabel
Espildora, Francisco
Aguilar-Hurtado, María Carmen
Hidalgo Conde, Ana
Arnedo Díez de los Ríos, Rocío
Cabrera César, Eva
Redondo-Rodriguez, Rocío
Velloso-Feijoo, María Luisa
Fernández-Nebro, Antonio
Safety and Effectiveness of Abatacept in a Prospective Cohort of Patients with Rheumatoid Arthritis–Associated Interstitial Lung Disease
title Safety and Effectiveness of Abatacept in a Prospective Cohort of Patients with Rheumatoid Arthritis–Associated Interstitial Lung Disease
title_full Safety and Effectiveness of Abatacept in a Prospective Cohort of Patients with Rheumatoid Arthritis–Associated Interstitial Lung Disease
title_fullStr Safety and Effectiveness of Abatacept in a Prospective Cohort of Patients with Rheumatoid Arthritis–Associated Interstitial Lung Disease
title_full_unstemmed Safety and Effectiveness of Abatacept in a Prospective Cohort of Patients with Rheumatoid Arthritis–Associated Interstitial Lung Disease
title_short Safety and Effectiveness of Abatacept in a Prospective Cohort of Patients with Rheumatoid Arthritis–Associated Interstitial Lung Disease
title_sort safety and effectiveness of abatacept in a prospective cohort of patients with rheumatoid arthritis–associated interstitial lung disease
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9313094/
https://www.ncbi.nlm.nih.gov/pubmed/35884786
http://dx.doi.org/10.3390/biomedicines10071480
work_keys_str_mv AT menavazqueznatalia safetyandeffectivenessofabataceptinaprospectivecohortofpatientswithrheumatoidarthritisassociatedinterstitiallungdisease
AT rojasgimenezmarta safetyandeffectivenessofabataceptinaprospectivecohortofpatientswithrheumatoidarthritisassociatedinterstitiallungdisease
AT fuegovarelaclara safetyandeffectivenessofabataceptinaprospectivecohortofpatientswithrheumatoidarthritisassociatedinterstitiallungdisease
AT garciastuderaimara safetyandeffectivenessofabataceptinaprospectivecohortofpatientswithrheumatoidarthritisassociatedinterstitiallungdisease
AT perezgomeznair safetyandeffectivenessofabataceptinaprospectivecohortofpatientswithrheumatoidarthritisassociatedinterstitiallungdisease
AT romerobarcocarmenmaria safetyandeffectivenessofabataceptinaprospectivecohortofpatientswithrheumatoidarthritisassociatedinterstitiallungdisease
AT godoynavarretefranciscojavier safetyandeffectivenessofabataceptinaprospectivecohortofpatientswithrheumatoidarthritisassociatedinterstitiallungdisease
AT manriquearijasara safetyandeffectivenessofabataceptinaprospectivecohortofpatientswithrheumatoidarthritisassociatedinterstitiallungdisease
AT gandiamartinezmyriam safetyandeffectivenessofabataceptinaprospectivecohortofpatientswithrheumatoidarthritisassociatedinterstitiallungdisease
AT calvogutierrezjerusalem safetyandeffectivenessofabataceptinaprospectivecohortofpatientswithrheumatoidarthritisassociatedinterstitiallungdisease
AT moralesgarridopilar safetyandeffectivenessofabataceptinaprospectivecohortofpatientswithrheumatoidarthritisassociatedinterstitiallungdisease
AT mourinorodriguezcoral safetyandeffectivenessofabataceptinaprospectivecohortofpatientswithrheumatoidarthritisassociatedinterstitiallungdisease
AT castroperezpatricia safetyandeffectivenessofabataceptinaprospectivecohortofpatientswithrheumatoidarthritisassociatedinterstitiallungdisease
AT anononateisabel safetyandeffectivenessofabataceptinaprospectivecohortofpatientswithrheumatoidarthritisassociatedinterstitiallungdisease
AT espildorafrancisco safetyandeffectivenessofabataceptinaprospectivecohortofpatientswithrheumatoidarthritisassociatedinterstitiallungdisease
AT aguilarhurtadomariacarmen safetyandeffectivenessofabataceptinaprospectivecohortofpatientswithrheumatoidarthritisassociatedinterstitiallungdisease
AT hidalgocondeana safetyandeffectivenessofabataceptinaprospectivecohortofpatientswithrheumatoidarthritisassociatedinterstitiallungdisease
AT arnedodiezdelosriosrocio safetyandeffectivenessofabataceptinaprospectivecohortofpatientswithrheumatoidarthritisassociatedinterstitiallungdisease
AT cabreracesareva safetyandeffectivenessofabataceptinaprospectivecohortofpatientswithrheumatoidarthritisassociatedinterstitiallungdisease
AT redondorodriguezrocio safetyandeffectivenessofabataceptinaprospectivecohortofpatientswithrheumatoidarthritisassociatedinterstitiallungdisease
AT vellosofeijoomarialuisa safetyandeffectivenessofabataceptinaprospectivecohortofpatientswithrheumatoidarthritisassociatedinterstitiallungdisease
AT fernandeznebroantonio safetyandeffectivenessofabataceptinaprospectivecohortofpatientswithrheumatoidarthritisassociatedinterstitiallungdisease